XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
G
G

Gilead

市场新闻

Reuters - 8小时前

Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries

Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries Oct 2 (Reuters) - Gilead Sciences GILD.O said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries. The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such as Botswana, Ethiopia and Kenya, until t
G
Reuters - 1天前

EU withdraws marketing authorisation for Abbvie's hepatitis C drug

UPDATE 2-EU withdraws marketing authorisation for Abbvie's hepatitis C drug Adds background in paragraphs 5 to 7 Oct 1 (Reuters) - The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's ABBV.N hepatitis C drug Exviera at the request of the company. The regulator said it withdrew the authorisation on Sept.
G
Reuters - 2天前

Kailera jumps on weight-loss drug bandwagon with $400 mln early-stage funding

UPDATE 3-Kailera jumps on weight-loss drug bandwagon with $400 mln early-stage funding Adds comments from CEO interview in paragraphs 4 and 8 By Niket Nishant Oct 1 (Reuters) - Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $400 million in early-stage funding.
G
Reuters - 5天前

U.S. earnings week ahead

DIARY-U.S. earnings week ahead Sept 27 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 30-Sep-2024 AMC POCI.O Precision Optics Corporation Inc Q4 2024 Precision Optics Corporation Inc Earnings Release 30-Sep-2024 AMC TRAK Repositrak Inc Q4 2024 Park City Group Inc Earnings Release 30-Sep-2024 10:30 ENS EnerSys EnerSys Tech Talk: Lithi
G
N
P
U
L
M
Reuters - 1周前

FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial

BRIEF-FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial Sept 23 (Reuters) - FDA: FDA: GILEAD ISSUES VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF VEKLURY (REMDESIVIR) FOR INJECTION 100 MG/VIAL DUE TO THE PRESENCE OF A GLASS PARTICLE FDA: GILEAD PRODUCT RECALLED IS LYOPHILIZED FORM OF VEKLURY FOR INJECTIO
G
Reuters - 3周前

U.S. STOCKS Unity Software, Viking Holdings, Adobe

BUZZ-U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed in choppy trading on Thursday after higher-than-expected producer prices data kept a smaller 25-basis point rate cut by the Fed firmly on the table, while Moderna slumped following a downbeat revenue forecast.
A
G
K
M
U
U
U
D
A
Reuters - 3周前

U.S. STOCKS Gold miners, silver miners, Warner Bros Discovery

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was little changed on Thursday after hot producer prices data kept a smaller, 25-basis-point interest-rate cut by the Federal Reserve firmly on the table, while vaccine maker Moderna's shares slumped following a downbeat revenue forecast.
G
K
M
U
U
D
W
A
Reuters - 3周前

Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada

BUZZ-Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada ** Shares of drugmaker Gilead GILD.O rise nearly 2% to $82.55 ** Co says its HIV injectable drug lenacapavir reduced HIV infections by 96% and was superior to daily pill Truvada in second late-stage trial ** The study included cisgender men, transgender men, tra
G
Reuters - 3周前

U.S. Cintas, Sprouts Farmers Market, Voya Financial

U.S. RESEARCH ROUNDUP-Cintas, Sprouts Farmers Market, Voya Financial Sept 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas Corp, Sprouts Farmers market and Voya Financial, on Thursday. HIGHLIGHTS * Ally Financial Inc ALLY.N : RBC cuts target price to $40 from $49 * Cintas Corp CTAS.O : CFRA adjusts target price to $170 from $645 to reflect 4-for-1 stock split * Gilead GILD.O : Raymond James raises target pri
C
E
G
L
N
P
S
E
A
D
E
L
Reuters - 3周前

US FDA staff questions confirmatory trial data for Intercept's liver disease drug

UPDATE 2-US FDA staff questions confirmatory trial data for Intercept's liver disease drug Rewrites paragraph 1, adds details from FDA and company's briefing documents in paragraphs 7, 8 and 9 and background in paragraphs 10 and 11 Sept 11 (Reuters) - Staff reviewers at the U.S. Food and Drug Administration said on Wednesday a confirmatory trial did not show the effectiveness of Intercept's liver disease drug, which received the health regulator's accelerated nod in 2016. Under the accelerated p
G
Reuters - 1个月前

U.S. Centerspace, Neurocrine Biosciences, 1-800-Flowers.com

U.S. RESEARCH ROUNDUP-Centerspace, Neurocrine Biosciences, 1-800-Flowers.com Aug 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspace, Neurocrine Biosciences and Veeva Systems, on Thursday. HIGHLIGHTS * Air Products APD.N : Berenberg raises target price to $275 from $240 * Centerspace CSR.N : Raymond James raises target price to $82 from $75 * Neurocrine Biosciences Inc NBIX.O : Piper Sandler raises to over
A
G
M
N
N
S
A
D
E
E
A
E
P
Reuters - 1个月前

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +2.0% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% Copart Inc CPRT.OQ +1.2% Verisk Analytics Inc VRSK.OQ +1.2% Old Dominion Freight Line Inc ODFL.OQ +1.1% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -25.1% PDD Holdings Inc PDD.OQ -6.3% Arm Holdings PLC ARM.OQ -5.5% Lululemon Athletica Inc LULU.OQ -4.4% Micron Technology Inc MU.OQ -4.3%
G
L
M
V
V
U
P
C
O
Reuters - 1个月前

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Insulet Corp PODD.OQ +3.9% Bristol-Myers Squibb Co BMY.N +2.9% Bio Rad Laboratories Inc BIO.N +2.1% Gilead Sciences Inc GILD.OQ +2.0% International Flavors & Fragrances Inc IFF.N +1.9% Bottom Performers Percent Change Super Micro Compu
G
L
M
U
I
Reuters - 1个月前

U.S. Alamo Group, Cognizant, Moderna

CORRECTED-U.S. RESEARCH ROUNDUP- Alamo Group, Cognizant, Moderna Corrects ESS Tech Inc entry to say Deutsche Bank adjusts PT to $9 from $0.90 to reflect 1-for-15 reverse stock split Aug 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alamo Group, Cognizant and Moderna, on Wednesday.
C
G
M
S
U
C
E
P
Reuters - 2个月前

PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI®

BRIEF-PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI® Aug 16 (Reuters) - PANTHERx Rare Pharmacy- PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI®
G
Reuters - 2个月前

Incyte's blood cancer drug succeeds late-stage trial

Incyte's blood cancer drug succeeds late-stage trial Aug 15 (Reuters) - Incyte INCY.O said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer. The company said its drug Monjuvi, combined with Bristol Myers Squibb's BMY.N drug, Revlimid, and Biogen's BIIB.O Rituxan achieved progression free survival in patients with follicular lymphoma (FL), when compared to Rituxan and Revlimid alone.
B
G
I
N
Reuters - 2个月前

U.S. Allstate, bluebird bio , Vicinity Motor

U.S. RESEARCH ROUNDUP-Allstate, bluebird bio , Vicinity Motor Aug 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allstate, bluebird bio and Vicinity Motor, on Thursday. HIGHLIGHTS * Allstate Corp ALL.N : CFRA cuts to hold from buy * Autodesk Inc ADSK.O : Baird raises target price to $295 from $289 * bluebird bio Inc BLUE.O : JP Morgan cuts to neutral from overweight * Provident Financial Services Inc PFS.N : KBW
A
A
C
G
I
K
D
A
Reuters - 2个月前

Gilead gets US FDA approval for inflammatory liver disease drug

UPDATE 3-Gilead gets US FDA approval for inflammatory liver disease drug Adds pricing in paragraph 4, company comments in paragraphs 6-7, details on common symptom in paragraphs 10-12 By Puyaan Singh and Leroy Leo Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' GILD.O liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics earlier this year.
G
I
Reuters - 2个月前

FDA Approves Gilead's Livdelzi For Primary Biliary Cholangitis - Website

BRIEF-FDA Approves Gilead's Livdelzi For Primary Biliary Cholangitis - Website Aug 14 (Reuters) - FDA: FDA APPROVES GILEAD'S LIVDELZI FOR PRIMARY BILIARY CHOLANGITIS - WEBSITE Further company coverage: GILD.O
G
Reuters - 2个月前

US FDA approves Gilead's liver disease drug

US FDA approves Gilead's liver disease drug Aug 14 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' GILD.O drug for a chronic and potentially fatal liver disease that mostly affects women. The disease, primary biliary cholangitis (PBC), causes inflammation of the small bile ducts in the liver and can eventually destroy them.
G

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。